Stock Screener App

Frei -

Installieren

24.70

3.83% 0.91

after-market

Handel nachbörslich: 24.70

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc.RARE - The Malaysian Reserve

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With - GuruFocus

Ultragenyx Puts BLA for MPS IIIA Gene Therapy UX111 in Front of FDA Again - CGTLive®

INVESTOR DEADLINE: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Business Wire

Berger Montague PC Investigating Claims on Behalf of Investors in Ultragenyx Pharmaceutical Inc. After Class Action Filing (NASDAQ: RARE) - marketscreener.com

RARE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ultragenyx Pharmaceutical Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - accessnewswire.com

RARE Investor Alert: Faruqi & Faruqi, LLP Reminds Ultragenyx (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - PR Newswire

Ultragenyx Pharmaceutical Class Action Reminder for Investors - intellectia.ai

RARE Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against Ultragenyx Pharmaceutical Inc. - PR Newswire

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - PharmiWeb.com

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with - PharmiWeb.com

Ultragenyx Pharmaceutical Class Action Lawsuit Notification - intellectia.ai

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - Business Wire

Class Action Lawsuit Reminder Against Ultragenyx Pharmaceutical Inc. - intellectia.ai

ULTRAGENYX ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update - marketscreener.com

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical - GlobeNewswire

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical - GlobeNewswire Inc.

Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm - PharmiWeb.com

Cell therapy weekly: advocacy groups push to restore Tecartus access - RegMedNet

Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz

Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm for Information About Their Rights - Business Wire

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx - GlobeNewswire

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Ultragenyx Pharmaceutical Inc. (RARE) ... - Caledonian Record

INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire

INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - Chartmill

A Look At Ultragenyx Pharmaceutical (RARE) Valuation After UX111 Data And BLA Resubmission - Yahoo Finance

Did Positive UX111 Gene Therapy Data And FDA Resubmission Just Shift Ultragenyx Pharmaceutical's (RARE) Investment Narrative? - Yahoo Finance

Ultragenyx’s gene therapy shows sustained improvements in MPS IIIA - Clinical Trials Arena

Ultragenyx Pharmaceutical (RARE) Expected to Announce Earnings on Thursday - MarketBeat

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Pfizer (PFE) - The Globe and Mail

Ultragenyx Faces Shareholder Class Action Lawsuit - intellectia.ai

Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead the Ultragenyx Class Action Lawsuit – RGRD Law - marketscreener.com

INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewswire

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit - The AI Journal

Ultragenyx Pharmaceutical Accused of Misleading Investors - intellectia.ai

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire

The Technical Signals Behind (RARE) That Institutions Follow - Stock Traders Daily

WCM Investment Management LLC Raises Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Ultragenyx Pharma stock holds steady as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com South Africa

Ultragenyx Pharmaceutical Inc. (RARE) Stock Analysis: Exploring A 158% Upside Potential - DirectorsTalk Interviews

9 Analysts Have This To Say About Ultragenyx Pharmaceutical - Benzinga

Biopharma bites: Updated data for Ultragenyx's gene therapy, AI newco's $13.5M seed round, plus more from NMD, Vertex - FirstWord Pharma

Ultragenyx recovers some losses as Jefferies sees potential 2026 rebound - MSN

Ultragenyx Under Investigation After 87.64% Stock Drop Following Phase 3 Study Results - intellectia.ai

Howard Horn Sells 3,061 Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock - MarketBeat

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE - Chartmill

Insider Sell: Howard Horn Sells Shares of Ultragenyx Pharmaceuti - GuruFocus

Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder - Benzinga

Ultragenyx (RARE) CFO Horn sells $72k in stock By Investing.com - Investing.com South Africa

Ultragenyx (RARE) CFO Horn sells $72k in stock - Investing.com

Ultragenyx Pharmaceutical Inc. Announces Long-Term Clinical Data Show Durable Benefits and Favorable Safety for UX111 Gene Therapy - marketscreener.com

HC Wainwright Reaffirms "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE) - MarketBeat

Ultragenyx Highlights New UX111 Data in FDA Resubmission - TipRanks

Ultragenyx (RARE) Reveals Promising Long-Term Results for Gene T - GuruFocus

RARE: HC Wainwright & Co. Reiterates Buy Rating with $60 Target - GuruFocus

Ultragenyx Pharma stock holds steady as H.C. Wainwright reiterates Buy rating - Investing.com Nigeria

Ultragenyx Pharmaceutical Reports Positive UX111 Study Results - TradingView

Ultragenyx Pharmaceutical Inc. Reports Promising Long-Term Results for UX111 Gene Therapy in Sanfilippo Syndrome Type A and Resubmits BLA to FDA - Quiver Quantitative

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Do - The Manila Times

Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome - Finviz

Ultragenyx BLA Resubmission Puts UX111 And RARE Valuation In Focus - Sahm

Federated Hermes Inc. Trims Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Ultragenyx completes rolling FDA submission for US approval of gene therapy - MSN

Why Ultragenyx shares fell despite resubmitting its gene therapy? | Tap to know more | Inshorts - Inshorts

GMAB

$30.90

0.23%

RPRX

$44.65

1.25%

INCY

$108.39

5.48%

BNTX

$106.62

1.02%

INSM

$149.86

0.77%

ONC

$353.92

1.99%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters